Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

As Gilead Seeks New CEO, Second Quarter Shows Stability

Jul 26 2018

• By Emily Hayes and Joseph Haas

Inscription "Q2" on PC screen. Financial data as background.

Related Content

HIV Market Snapshot: Gilead's Biktarvy Set To Soar, But ViiV May Win In The End

Apr 18 2018

Yescarta One Of Few Gilead Bright Spots, And Now It Has A Competing CAR-T

May 02 2018

Interview: Measured Launch, Long Future For Gilead CAR-T In Europe

Jul 09 2018

Cosentyx Carries Novartis Sales But Kymriah Manufacturing Gives Cause For Concern

Jul 18 2018

Gilead's Biktarvy Approval Heightens HIV Competition With ViiV

Feb 07 2018

Milligan’s Retirement Means New CEO For New Gilead

Jul 26 2018

New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib

Apr 20 2018

Genfit's Enrollment Delay In NASH May Aid Intercept's First-To-Market Goal

Apr 25 2017

Related Companies

Gilead Sciences, Inc.

Novartis AG

Intercept Pharmaceuticals, Inc.

Genfit SA

Kite Pharma, Inc.

Additional Topics

Sales & Earnings Launches Regenerative Medicine Companies Commercial BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window